Peptide conjugated anti-cancer prodrugs
AssigneeBiosight Ltd.
InventorStela Gengrinovitch
Life of this patent
Estimating the term…
Abstract
The present invention relates to prodrug molecules comprising conjugates of an antiproliferative drug, a protease specific cleavable peptide, and, optionally, a targeting peptide, with the prodrugs being substantially inactive prior to degradation of the cleavable sequence by proteolytic enzymes abundant within or in close proximity to the target cancer cell. Also, pharmaceutical compositions of the conjugates and the use of these compositions for treatment of cancer are disclosed.
Claims21
A prodrug comprising a conjugate of at least one antiproliferative drug molecule covalently coupled directly or via a linker to a peptide moiety, said peptide moiety being specifically cleavable by an asparaginyl protease abundant in or secreted by malignant cells, thereby preferentially releasing the antiproliferative drug molecule within or at the malignant cells by the cleaving action of the asparaginyl protease.
Dependencies are inferred from the claim text.